TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification

Title:TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification

Volume: 20 Issue: 1

Author(s): Lu Miao*, Buze Chen, Li Jing, Tian Zeng and Youguo Chen*

Affiliation:

• Department of Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215026, Suzhou, Jiangsu, China
• Department of Gynecology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221009, Jiangsu, China

• Department of Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215026, Suzhou, Jiangsu, China

Keywords: Uterine corpus endometrial carcinoma, TPD52, prognosis, immune infiltration, MSI, mRNAsi, ceRNA

Abstract:

Background: Aberrant expression of tumor protein D52 (TPD52) is associated with some tumors. The role of TPD52 in uterine corpus endometrial carcinoma (UCEC) remains uncertain.

Objective: We aimed to investigate the involvement of TPD52 in the pathogenesis of UCEC.

Methods: We employed bioinformatics analysis and experimental validation in our study.

Results: Our findings indicated that elevated TPD52 expression in UCEC was significantly associated with various clinical factors, including clinical stage, race, weight, body mass index (BMI), histological type, histological grade, surgical approach, and age (p < 0.01). Furthermore, high TPD52 expression was a predictor of poorer overall survival (OS), progress-free survival (PFS), and disease-specific survival (DSS) (p = 0.011, p = 0.006, and p = 0.003, respectively). TPD52 exhibited a significant correlation with DSS (HR: 2.500; 95% CI: 1.153-5.419; p = 0.02). TPD52 was involved in GPCR ligand binding and formation of the cornified envelope in UCEC. Moreover, TPD52 expression was found to be associated with immune infiltration, immune checkpoints, tumor mutation burden (TMB)/ microsatellite instability (MSI), and mRNA stemness indices (mRNAsi). The somatic mutation rate of TPD52 in UCEC was 1.9%. A ceRNA network of AC011447.7/miR-1-3p/TPD52 was constructed. There was excessive TPD52 protein expression. The upregulation of TPD52 expression in UCEC cell lines was found to be statistically significant.

Conclusion: TPD52 is upregulated in UCEC and may be a useful patent for prognostic biomarkers of UCEC, which may have important value for clinical treatment and supervision of UCEC patients.

Cite this article as:

Miao Lu*, Chen Buze, Jing Li, Zeng Tian and Chen Youguo*, TPD52 as a Potential Prognostic Biomarker and its Correlation with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma: Bioinformatic Analysis and Experimental Verification, Recent Patents on Anti-Cancer Drug Discovery 2025; 20 (1) . https://dx.doi.org/10.2174/0115748928267447231107101539